



ELSEVIER

Contents lists available at [SciVerse ScienceDirect](http://www.sciencedirect.com)

Comptes Rendus Chimie

www.sciencedirect.com

Full paper/Mémoire

Tungstate sulfuric acid as an efficient catalyst for the synthesis of benzoxazoles and benzothiazoles under solvent-free conditions

Mahnaz Farahi, Bahador Karami*, Masume Azari

Department of Chemistry, Yasouj University, Yasouj 75918–74831, Iran

ARTICLE INFO

Article history:

Received 18 January 2013

Accepted after revision 21 March 2013

Available online 18 May 2013

Keywords:

Heterogeneous catalysis

Tungstate sulfuric acid

Benzoxazoles

Benzothiazoles

Orthoesters

ABSTRACT

Tungstate sulfuric acid (TSA) has been found to be an efficient and reusable catalyst for the synthesis of benzoxazole and benzothiazole derivatives via reactions of orthoesters with *o*-aminophenols or *o*-aminothiophenols in high yields.

© 2013 Published by Elsevier Masson SAS on behalf of Académie des sciences.

1. Introduction

Heterogeneous solid catalysts have gained much attention in recent years, as they possess a number of advantages, such as cleaner reaction, easier work-up, reduced reaction time, and eco-friendliness [1,2]. These considerations are currently driving our effort to develop heterogeneous organic transformations. Tungstate sulfuric acid (TSA) is an alternative to sulfuric acid that was synthesized by the reaction of anhydrous sodium tungstate with chlorosulfonic acid [3]. This new inorganic solid acid has been applied as an efficient catalyst to a variety of organic transformations [4–7].

There has been considerable interest in benzoxazole and benzothiazole derivatives, not least because of their value for a variety of industrial [8,9], biological [10,11], and medicinal chemistry uses [12,13]. Furthermore, these compounds have shown different pharmacological activities, such as anti-HIV [14,15], antitumor [16,17], anticancer [18,19], antibacterial [20,21], and anti-inflammatory [22,23] properties. The extensive applications of

these compounds have prompted wide studies for their synthesis. The most frequently used synthetic method to produce benzoxazole and benzothiazole derivatives consists of the condensation of *o*-aminophenol or *o*-aminobenzenethiol with substituted aldehydes, nitriles, acyl chlorides, or carboxylic acids [13]. However, the majority of these methods suffer from certain drawbacks, for instance, the use of hazardous solvents and catalysts, high cost, long reaction times, and drastic reaction conditions.


In continuation of our interest in the use of heterogeneous solid catalysts [24–26], we wish to report herein a very simple procedure for the synthesis of benzoxazole (4) and benzothiazole (5) derivatives using TSA as a superior solid acid catalyst (Scheme 1).

2. Results and discussion

In a first set of experiments, the solvent-free reaction of *o*-aminophenol (1 mmol) and triethyl orthoacetate (1.1 mmol) was performed at room temperature in the absence of the catalyst as a model reaction. No benzoxazole product was synthesized, even after 24 h. Therefore, the model reaction was investigated in the presence of different catalysts, under various conditions (Table 1).

* Corresponding author.

E-mail address: karami@mail.yu.ac.ir (B. Karami).



Scheme 1. Tungstate sulfuric acid-catalyzed synthesis of benzoxazoles and benzothiazoles.

Table 1
Optimization of the reaction.

Entry	Solvent	Catalyst (mol%)	Temperature (°C)	Time (min)	Yield (%) ^a
1	None	None	90–100	360	50
2	None	ZnCl ₂ (5)	60–70	240	60
3	None	MgBr ₂ (5)	60–70	180	70
4	None	H ₂ SO ₄ (5)	60–70	120	50
5	None	TSA (1)	60–70	25	87
6	None	TSA (5)	60–70	30	85
7	None	TSA (10)	60–70	30	80
8	None	TSA (1)	80–90	8	96
9	None	TSA (1)	100	10	95
10	EtOH	TSA (1)	70	120	65
11	CH ₃ CN	TSA (1)	70–80	120	60
12	H ₂ O	TSA (1)	100	180	45

^a Isolated yields.

As it can be seen, the best results were obtained by performing the model reaction in the presence of 1 mol% of TSA at 80–90 °C under solvent-free conditions.

Then, the generality of the procedure was evaluated by the reaction of various orthoesters (3) with *o*-aminophenols (1) and *o*-aminothiophenols (2) under optimized reaction conditions. It was found that both electron-rich and electron-poor *o*-aminophenols (Me, Cl and NO₂ as donating and withdrawing groups) reacted well in this process to afford the corresponding products in good to excellent yields. The obtained results are summarized in Table 2.


The products were isolated and characterized by physical and spectroscopic techniques and they were compared with authentic samples [28–32].

The probable mechanism for the formation of benzoxazoles and benzothiazoles is outlined in Scheme 2. Initially,

orthoester is activated by TSA to give 6 and then 7. Next, *o*-aminophenol or *o*-aminothiophenol attacks 7, affording 8, which is then activated by the catalyst to give 9. Cyclization of 10 gives 11, which in turn is activated by the catalyst to afford the final product.































The reusability of the catalyst is important for the large-scale operation and from an industrial point of view. Therefore, the recovery and reusability of TSA was examined. Hence, TSA was regenerated from the model reaction by washing with chloroform and drying at 120 °C.

The major advantages of the presented protocol over the existing methods can be seen by comparing our results with those of some recently reported procedures, as shown in Table 3. For example use of *o*-benzenedisulfonimide required long reaction times. And use of Silica sulfuric acid as catalyst requires high temperature.



Scheme 2. The proposed mechanism for tungstate sulfuric acid-catalyzed formation of benzoxazoles and benzothiazoles.

Table 2
Synthesis of benzoxazole and benzothiazole derivatives in the presence of tungstate sulfuric acid (1 mol%).

Entry	2-Aminophenol or 2-aminothiophenol	Orthoester	Product	Time (min)	Yield (%) ^a	M.P. (°C) [Reference]
4a		HC(OEt) ₃		7	92	Oil [27]
4b		MeC(OEt) ₃		9	98	Oil [27]
4c		EtC(OEt) ₃		4	98	Oil [27]
4d		HC(OEt) ₃		7	90	43–45 [27]
4e		MeC(OEt) ₃		6	90	Oil [27]
4f		EtC(OEt) ₃		12	88	29–30 [27]
4g		HC(OEt) ₃		10	84	146–148
4h		MeC(OEt) ₃		9	80	128–129
4i		EtC(OEt) ₃		10	93	150–152
4j		HC(OEt) ₃		4	96	36–38 [27]
4k		MeC(OEt) ₃		7	97	53–55 [27]
4l		EtC(OEt) ₃		10	90	58–59 [27]
5a		HC(OEt) ₃		7	89	Oil [27]
5b		MeC(OEt) ₃		4	91	Oil [27]
5c		EtC(OEt) ₃		6	94	Oil [27]

^a Isolated yields.

Table 3
Comparison of the results for the preparation of 2-methyl benzoxazole with various used catalysts.

Catalyst	Mol%	Time (min)	Temperature	Yield (%) [Reference]
<i>o</i> -Benzenedisulfonimide	5	120–240	R.T.	85–93 [28]
Ga(OTf)	10	5–90	R.T.	71–98 [29]
HBF ₄ –SiO ₂	2	45–60	R.T.	91–97 [30]
Bi salts	0.5–4	1–10	85 °C	80–93 [31]
Silica sulfuric acid	50 mg	2–10	85 °C	85–97 [32]

R.T.: room temperature.




Fig. 1. (a) Powder X-ray diffraction pattern of the tungstate sulfuric acid (TSA); (b) FT-IR spectra of $\text{H}_3\text{OSO}(\text{WO}_2)\text{OSO}_3\text{H}$ (TSA).

3. Characterization of the catalyst

Fig. 1a shows the X-ray diffraction analysis (XRD) patterns of TSA. It was reported that high-degree mixing of W–S in chlorosulfonic acid often led to the absence of the XRD pattern for anhydrous sodium tungstate. The broad peak around 25.7° (2θ) (θ is the Bragg angle) from the smaller inset could be attributed to the linking of WO_3 into the chlorosulfonic acid.

The FT-IR spectra of anhydrous sodium tungstate and TSA are shown in Fig. 2b. The spectrum of TSA shows the characteristic bonds of anhydrous sodium tungstate and chlorosulfonic acid. The wavenumbers 3406, 1820, 1725,

1702, 1620, 1290, 1060, 1005 and 860 cm^{-1} in the catalyst's spectra reveal bonds in both anhydrous sodium tungstate and the $-\text{OSO}_3\text{H}$ group. Hence, the titration of the catalyst with NaOH (0.1 N) was done. Firstly, 1 mmol of catalyst was dissolved in 100 mL of water. Therefore, the titration with NaOH (0.1 N) in the presence of phenolphthalein was carried out. At the endpoint of the titration, 4 mmol of the titrant was consumed. Also, based on potentiometric data, the $\text{pK}_{\text{a}1}$ value for TSA is 3.17 and $\text{pK}_{\text{a}2}$ is 8.78. The result of the catalyst's titration showed four acidic valences because of hydrolysis in aqueous solvent. The X-ray fluorescence (XRF) data of TSA indicates the presence of WO_4 and SO_3 in this catalyst (Table 4).




Fig. 2. Reusability study of the catalyst in the model reaction.

Table 4
XRF data of $\text{HO}_3\text{SO}(\text{WO}_2)\text{OSO}_3\text{H}$ (TSA).

Compound	Concentration (%W/W)
WO_4	19.49
SO_3	0.317
Na_2O	0.190
Cl	0.056
CuO	0.023
Fe_2O_3	0.015
CaO	0.014
LOI ^a	79.82
Total	99.93

^a Loss on ignition.

4. Conclusion

In conclusion, TSA was found to be a mild and efficient catalyst for the formation of benzoxazoles and benzothiazoles. The use of this reusable catalyst under solvent-free conditions has made this protocol practical, environmentally friendly and economically attractive. The simple work-up procedure, the mild reaction conditions, the short reaction times, the high yields of products and the non-toxicity of the catalyst are other advantages of the present method.

5. Experimental

5.1. General

XRD patterns were obtained with a Philips X Pert Pro X diffractometer operated with a Ni-filtered Cu K α radiation source. XRF spectroscopy spectra were recorded with the X-ray fluorescence analyzer S₄ Pioneer, Bruker, Germany. The chemicals were purchased from Aldrich, Fluka and Merck chemical companies and freshly used without purification. The products were isolated and identified by their spectral data. IR spectra were recorded on a FT-IR JASCO-680 using KBr disks. The ¹H NMR and ¹³C NMR spectra were recorded with a Bruker 400 Ultrashield[®] (400 MHz), with CDCl₃ as the solvent.

5.2. Preparation of the catalyst

TSA was prepared via the previously reported procedure [3]. First, anhydrous sodium tungstate (2 mmol, 5.876 g) was added to dry *n*-hexane (25 mL) in a 100-mL round bottom flask, equipped with an ice bath and overhead stirrer. Chlorosulfonic acid (4 mmol, 0.266 mL) was then added dropwise to the flask during 30 min and stirred for 1.5 h. Afterwards, the reaction mixture was gradually poured into 25 mL of chilled distilled water under agitation. The TSA was separated as a yellowish solid by filtration, washed with distilled water five times till the filtrate showed a negative test for the chloride ion, and dried at 120 °C for 5 h. The yield of the obtained yellowish catalyst proved to be 98% after it was decomposed at 285 °C.

5.3. Reusability of the catalyst

At the end of the reaction of *o*-aminophenol (1 mmol), triethyl orthoacetate (1.1 mmol) and TSA (1 mol%), the catalyst was filtered, washed with chloroform, and dried at 120 °C for 1 h. Using the recycled catalyst for five consecutive times in the model reaction afforded the product with a gradual decrease in the reaction yield. The results of these observations are shown in Fig. 2.

5.4. General procedure for the synthesis of benzoxazole and benzothiazole derivatives

To a mixture of orthoester (1.1 mmol) and *o*-aminophenol or *o*-aminothiophenol (1 mmol) was added TSA (1 mol%). The mixture was stirred at 80–90 °C for the

appropriate time according to Table 4. After the completion of the reaction (as indicated by TLC), the mixture was diluted with chloroform (10 mL) and the catalyst was separated by filtration. Further purification was achieved by column chromatography.

5.5. Selected spectral data

5.5.1. 2-Methylbenzoxazole (4b)

Colorless oil, FT-IR: ν_{\max} (KBr) = 3050, 2900, 1617, 1575, 1450, 1160 cm⁻¹, ¹H NMR (400 MHz, CDCl₃): δ = 2.61 (s, 3H, CH₃), 7.27 (m, 2H, CH arom), 7.44 (m, 1H, CH arom), 7.63 (m, 1H, CH arom) ppm, ¹³C NMR (100 MHz, CDCl₃): δ = 14.2, 110.7, 119.5, 124.0, 124.4, 141.5, 150.8, 163.5 ppm.

5.5.2. 2,5-Dimethylbenzoxazole (4e)

Colorless oil, FT-IR: ν_{\max} (KBr) = 3010, 2950, 1575, 1450, 1260, 610 cm⁻¹, ¹H NMR (400 MHz, CDCl₃): δ = 2.39 (s, 3H, CH₃), 2.55 (s, 3H, CH₃), 7.02 (d, *J* = 8.4 Hz, 1H, CH arom), 7.27 (d, *J* = 8.1 Hz, 1H, CH arom), 7.39 (s, 1H, CH arom) ppm, ¹³C NMR (100 MHz, CDCl₃): δ = 14.1, 22.5, 109.6, 119.5, 125.3, 133.4, 141.6, 149.1, 163.4 ppm.

5.5.3. 5-Nitrobenzoxazole (4g)

Yellow solid, mp 146–148 °C, FT-IR: ν_{\max} (KBr) = 3055, 1620, 1560, 1462, 1169 cm⁻¹, ¹H NMR (400 MHz, CDCl₃): δ = 7.27 (m, 1H, CH arom), 8.08 (m, 1H, CH arom), 8.18 (m, 1H, CH arom), 8.53 (s, 1H) ppm, ¹³C NMR (100 MHz, CDCl₃): δ = 111.42, 117.19, 121.75, 140.49, 145.47, 153.44, 155.23 ppm.

5.5.4. 2-Methyl-5-nitrobenzoxazole (4h)

White solid, mp 128–129 °C, FT-IR: ν_{\max} (KBr) = 3100, 3000, 1610, 1572, 1515, 1445, 1340, 1160 cm⁻¹, ¹H NMR (400 MHz, CDCl₃): δ = 2.52 (s, 3H, CH₃), 7.39 (d, *J* = 9.2 Hz, 1H, CH arom), 8.09 (dd, ³*J*_{HH} = 8.8 Hz, ⁴*J*_{HH} = 2 Hz, 1H, CH arom), 8.36 (d, *J* = 2 Hz, 1H, CH arom) ppm, ¹³C NMR (100 MHz, CDCl₃): δ = 14.9, 110.4, 115.8, 120.7, 141.9, 145.1, 154.5, 167.1 ppm.

5.5.5. 5-Chlorobenzoxazole (4j)

White solid, mp 36–38 °C, FT-IR: ν_{\max} (KBr) = 3100, 1600, 1576, 1445, 1160 cm⁻¹, ¹H NMR (400 MHz, CDCl₃): δ = 7.18 (d, *J* = 8.4 Hz, 1H, CH arom), 7.32 (d, *J* = 8.8 Hz, 1H, CH arom), 7.59 (s, 1H, CH arom), 7.92 (s, 1H) ppm, ¹³C NMR (100 MHz, CDCl₃): δ = 111.7, 120.6, 126.2, 130.2, 141.4, 148.6, 153.7 ppm.

5.5.6. 5-Chloro-2-ethylbenzoxazole (4l)

White solid, mp 59–61 °C, FT-IR: ν_{\max} (KBr) = 3050, 2800, 1600, 1560, 1440, 1160 cm⁻¹, ¹H NMR (400 MHz, CDCl₃): δ = 1.26 (t, *J* = 7.6 Hz, 3H, CH₃), 2.76 (q, *J* = 7.6 Hz, 2H, CH₂), 7.07 (m, 1H, CH arom), 7.2 (d, *J* = 8.4 Hz, 1H, CH arom), 7.45 (d, *J* = 1.2 Hz, 1H, CH arom) ppm, ¹³C NMR (100 MHz, CDCl₃): δ = 10.7, 22.1, 110.9, 124.6, 124.9, 129.4, 142.5, 149.4 ppm.

5.5.7. 2-Methylbenzothiazole (5b)

Pale yellow oil, FT-IR: ν_{\max} (KBr) = 3050, 2880, 1617, 1575, 1450, 1160 cm⁻¹, ¹H NMR (400 MHz, CDCl₃): δ = 2.84

(s, 3H, CH₃), 7.34 (t, *J* = 7.6 Hz, 1H, CH arom), 7.44 (t, *J* = 8.1 Hz, 1H, CH arom), 7.81 (d, *J* = 8.0 Hz, 1H, CH arom), 7.95 (d, *J* = 8.0 Hz, 1H, CH arom) ppm, ¹³C NMR (100 MHz, CDCl₃): δ = 20.1, 121.3, 122.6, 124.3, 126.1, 135.6, 153.3, 166.8 ppm.

Acknowledgement

We acknowledge the research council of Yasouj University.

References

- [1] G. Sartori, R. Maggi, *Chem. Rev.* 113 (2010) 1.
- [2] R. Bingig, S. Butt, I. Hartmann, M. Matthes, C. Thiel, *Catalysts* 2 (2012) 223.
- [3] B. Karami, M. Montazerzohouri, *Molecules* 11 (2008) 720.
- [4] B. Karami, Z. Haghighijou, M. Farahi, S. Khodabakhshi, *Phosphorus, Sulfur Silicon Relat. Elem.* 187 (2012) 754.
- [5] B. Karami, Z. Haghighijou, S. Khodabakhshi, *Chem. Papers* 66 (2012) 684.
- [6] B. Karami, S. Khodabakhshi, *J. Chin. Chem. Soc.* 59 (2012) 187.
- [7] B. Karami, S. Khodabakhshi, N. Safikhani, A. Arami, *Bull. Korean Chem. Soc.* 33 (2012) 123.
- [8] M. Belhouchet, C. Youssef, H.B. Ammar, R.B. Salem, T. Mhiri, *X-Ray Struct. Anal.* 28 (2012) 3.
- [9] H. Eshghi, M. Rahimizadeh, A. Shiri, P. Sedaghat, *Bull. Korean Chem. Soc.* 33 (2012) 515.
- [10] S.-I. Fukuzawa, E. Shimizu, Y. Atsuumi, M. Haga, K. Ogata, *Tetrahedron Lett.* 50 (2009) 2374.
- [11] A.A. Fadda, K.S. Mohamed, A. El-Faragy, *Int. J. Mol. Org. Chem.* 1 (2012) 193.
- [12] C. Praveen, A. Namdakumar, P. Dheenkumar, D. Muralidharan, P.T. Perumal, *J. Chem. Sci.* 124 (2012) 609.
- [13] X. Wen, J.E. Bakali, R. Deprez-Poulain, B. Deprez, *Tetrahedron Lett.* 53 (2012) 2440.
- [14] G. Satish, K.H.V. Reddy, K. Ramesh, K. Karnakar, Y.V.P. Nageswar, *Tetrahedron Lett.* 53 (2012) 2518.
- [15] T.H.M. Jonckers, M.C. Rouan, G. Hache, W. Schepens, S. Hallenberger, J. Baumeister, J.C. Sasaki, *Bioorg. Med. Chem. Lett.* 22 (2012) 4998.
- [16] P.S.M. Sommer, R.C. Almeida, K. Schneider, W. Beil, R.D. Sussmuth, H.P. Fiedler, *J. Antibiotics* 61 (2008) 683.
- [17] K. Wang, F.P. Guenqerich, *Chem. Rev. Toxicol.* 25 (2012) 1740.
- [18] S.-T. Huang, I.-J. Hsei, C. Chen, *Bioorg. Med. Chem.* 14 (2006) 6101.
- [19] A. Gupta, S. Rawat, S. Braun, *J. Curr. Pharma. Res.* 3 (2010) 13.
- [20] N. Park, Y. Heo, M.R. Kumar, Y. Kim, K.H. Song, S. Lee, *Eur. J. Org. Chem.* 2012 (2012) 1984.
- [21] S. Braun, A. Botzki, S. Salmen, C. Textor, G. Bernhardt, S. Dove, A. Buschaure, *Eur. J. Med. Chem.* 46 (2011) 4419.
- [22] W.M. Abdou, R.F. Barghash, A.A. Sediek, *Eur. J. Med. Chem.* 57 (2012) 362.
- [23] K.D. Niranjane, M.A. Kale, *Der Pharma. Lett.* 3 (2011) 276.
- [24] F. Tamaddon, M. Farahi, B. Karami, *J. Mol. Catal. A: Chem.* 337 (2011) 52.
- [25] B. Karami, S. Mallakpour, M. Farahi, *Heteroat. Chem.* 19 (2008) 389.
- [26] B. Karami, Z. Zare, K. Eskandari, *Chem. Papers* 67 (2013) 145.
- [27] I. Mohammadpoor-Baltork, A.R. Khosropour, S.F. Hojati, *Catal. Commun.* 8 (2007) 1865.
- [28] M. Barbero, S. Cadamuro, S. Dughera, *ARKIVOK* ix (2012) 262.
- [29] L. Juyan, L. Qian, X. Wei, W. Weilu, *Chin. J. Chem.* 29 (2011) 1739.
- [30] A.V. Patil, B.P. Bandgar, S.H. Lee, *Bull. Korean Chem. Soc.* 31 (2010) 1719.
- [31] I. Mahammadpoor-Baltork, A.R. Khosropour, S.F. Hojati, *Monatsh. Chem.* 138 (2007) 663.
- [32] I. Mahammadpoor-Baltork, M. Moghaddam, S. Tangestaninejad, V. Mirkhani, M.A. Zolfigol, S.F. Hojati, *J. Iran Chem. Soc.* 5 (2008) 65.